Machine-Based Learning Hierarchical Cluster Analysis: Sex-Based Differences in Prognosis Following Resection of Hepatocellular Carcinoma. World journal of surgery Resende, V., Tsilimigras, D. I., Endo, Y., Guglielmi, A., Ratti, F., Aldrighetti, L., Marques, H. P., Soubrane, O., Lam, V., Poultsides, G. A., Popescu, I., Alexandrescu, S., Gleisner, A., Martel, G., Hugh, T., Endo, I., Shen, F., Pawlik, T. M. 2023

Abstract

Patients with hepatocellular carcinoma (HCC) may have a heterogeneous presentation, as well as different long-term outcomes following surgical resection. We sought to use machine learning to cluster patients into different prognostic groups based on preoperative characteristics.Patients who underwent curative-intent liver resection for HCC between 2000 and 2020 were identified from a large international multi-institutional database. A hierarchical cluster analysis was performed based on preoperative factors to characterize patterns of presentation and define disease-free survival (DFS).Among 966 with HCC, 3 distinct clusters were identified: Cluster 1 (n?=?160, 16.5%), Cluster 2 (n?=?537, 55.6%) and Cluster 3 (n?=?269, 27.8%). Cluster 1 (n?=?160, 16.5%) consisted of female patients (n?=?160, 100%), low inflammation-based scores, intermediate tumor burden score (TBS) (median: 4.71) and high alpha-fetoprotein (AFP) levels (median 41.3 ng/mL); Cluster 2 consisted of male individuals (n?=?537, 100%), mainly with a history of HBV infection (n?=?429, 79.9%), low inflammation-based scores, intermediate AFP levels (median 26.0 ng/mL) and lower TBS (median 4.49); Cluster 3 was comprised of older patients (median age 68 years) predominantly male (n?=?248, 92.2%) who had low incidence of HBV/HCV infection (7.1% and 8.2%, respectively), intermediate AFP levels (median 16.8 ng/mL), high inflammation-based scores and high TBS (median 6.58). Median DFS worsened incrementally among the three different clusters with Cluster 3 having the lowest DFS (Cluster 1: median not reached; Cluster 2: 34 months, 95% CI 23.0-48.0, Cluster 3: 19 months, 95% CI 15.0-29.0, p?

View details for DOI 10.1007/s00268-023-07194-z

View details for PubMedID 37777670

View details for PubMedCentralID 10181349